The phase 3 4WARD trial is evaluating mavorixafor for reducing infection rates and raising neutrophil counts in patients with primary chronic neutropenia.
VGX-3100 met its composite primary end point in the phase 3 HPV-303CHN trial, supporting a nonsurgical treatment approach for HPV-16/18–associated cervical HSIL.